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ABSTRACT 
p27
Kip1 has been hypothesized to play a major role in carcinogenesis. Most of the 
published data reported that loss of p27
Kip1 expression was strongly associated 
with development and progression of tumour. The purpose of this study was to 
analyze  p27
Kip1  expression  in  normal,  benign  and  malignant  prostate  cancer 
tissues  and  their  association  with  the  clinicopathological  parameters.  The 
expression of p27
Kip1 was evaluated by an immunohistochemistry method. p27
Kip1 
expression  was  significantly  higher  in  normal  and  benign  prostate  tissues 
(P<0.01). In contrast, some malignant tissues had no p27
Kip1 expression and most 
had  weak  p27
Kip1  expression.  p27
Kip1  expression  was  found  to  be  decreased 
significantly  with  increasing  Gleason  scores  (P=0.003).  Most  of  prostate 
adenocarcinomas (PCa) with Gleason 8 and 9 showed loss of p27
Kip1 expression. 
The expression was also positively correlated with prostate specific antigen level 
and age in PCa group (P=0.003 and 0.043 respectively), whereas no association 
was found between the p27
Kip1 expression with tumour amount and age in benign 
prostatic hyperplasia group. This study suggests that loss of p27
Kip1expression is 
essential during development and progression of prostate cancer. 
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Introduction 
Prostate cancer is one of the most common cancers that 
occur in Malaysian male population and was ranked fourth 
among  all  human  cancers  prevalence.  Prostate 
adenocarcinoma is the most common type of prostate cancer 
(National  Cancer  Registry,  2007)  and  its  significance  is 
related not only to the mortality, but also to its association to 
the  high  morbidity  rate.  Furthermore,  there  is  no  standard 
treatment that effectively cures this disease (Valicenti et al., 
2000).  Management  of  cancer  patients  including  prostate 
cancer  highly  depends  on  accurate  assessment  of  the 
biological  potential  of  the  tumour.  Although  the  current 
assessment technique, which is focused on stage, grade and 
prostate  specific  antigen  (PSA),  is  widely  used, 
unfortunately, it is inadequate to determine the best treatment 
options to the patients. More precise marker is needed to aid 
treatment decisions for prostate cancer patients. 
It  has  been  postulated  that  loss  of  negative  cell  cycle 
regulator  might  have  a  role  in  tumour  development  and 
progression  (Sherr,  1996).  One  example  of  cell  cycle 
regulator is p27
Kip1. Loss of p27
Kip1 expression was seen in 
many  human  carcinomas  like  colorectal,  mammary, 
esophageal, pulmonary and gastric (Loda et al., 1997; Tan et 
al., 1997; Catzavelos et al., 1997; Porter et al., 1997; Mori et 
al.,  1997;  Esposito  et  al.,  1997;  Singh  et  al.,  1998).  In 
addition, loss of p27
Kip1 expression was also found to be a 
negative prognostic marker in prostate carcinoma (Tsihlias et 
al., 1998; Yang et al., 1998; Cheville et al., 1998; Cordon-
Cardo et al., 1998; Cote et al., 1998). p27
Kip1 is actually a 
protein that regulates the cell cycle transition from G1 to S 
phase by binding to and inhibiting several cyclin dependen 
kinase (CDK) protein complexes in normal cells. Increased 
p27
Kip1  protein  expression  levels  serves  as  a  barrier  for ISSN: 1314-6246  Roduan et al.  J. BioSci. Biotech. 2014, 3(2): 119-125. 
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progression to S phase and signal exit from cell cycle, thus, 
block  the  cell  proliferations (Polyak  et  al.,  1994).  Lower 
levels of p27
Kip1 expression also could predict recurrent and 
poor disease-free survival in prostate cancer and is associated 
with other prognostic factors including higher tumour grade, 
positive surgical margins, seminal vesicle involvement, and 
lymph node metastasis (Dong, 2006). 
In  the  present  study,  we  conducted  an 
immunohistochemical  analysis  to  evaluate  p27
Kip1  protein 
expression in normal, BPH and prostate adenocarcinoma. The 
possible  association  between  p27
Kip1  expressions  with 
clinicopathological parameters has also been assessed. 
Materials and Methods 
Samples 
263 paraffin embedded specimens collected between 2006 
and  2008  were  obtained  from  the  archive  of  Pathology 
Department  in  Hospital  Kuala  Lumpur.  The  patients’  age 
ranged from 28 to 91 years (mean age, 64.54 ﾱ 10.8 years). 
The specimens were composed of 63 normal prostate, 100 
BPH and 100 PCa tissues. All the PCa cases were classified 
according  to  the  Gleason  grading  system  and  were  further 
divided into low score group (Gleason 6 to 7) and high score 
group (Gleason 8 to 9). The tumour volumes were classified 
as low amount, ≤ 5% and high amount, > 5%. Pretreatment 
PSA  were  grouped  as  either  ≤  4.0  ng/ml  or  >  4.0  ng/ml. 
Ethical approvals were obtained from the ethical committee 
of  University  Putra  Malaysia  (UPM),  National  Medical 
Research Registration (NMRR) and Hospital Kuala Lumpur 
(HKL) prior to commencement of the study. 
Immunohistochemistry 
p27
Kip1 immunohistochemical staining was done using the 
DAKO REAL EnVision (Dako, Ca, USA).  A total of 263 
formalin-fixed  paraffin  embedded  tissues  samples  were 
processed. The paraffin blocks were cut at 4 µm, mounted 
onto poly-L-lysine glass slides and dried overnight at room 
temperature.  Sections  were  dewaxed  with  absolute  xylene 
and rehydrated with grading alcohol and lastly run under tap 
water. The sections then were heated in citrate buffer (0.01 
M, pH 6.0) in 1000 W microwave oven for 10 minutes high 
temperature  (98°C)  followed  by  10  minutes  medium  low 
temperature (72°C). After cooled down at room temperature 
for  20  minutes,  endogenous  peroxidase  activity  was 
inactivated in 3 % H2O2 for 5 minutes. Then, the sections 
were  rinse  twice  with  Tris  Buffered  Saline  (TBS)  for  5 
minutes.  Monoclonal  mouse  anti-human  p27
Kip1  (clone 
SX53G8,  Dako,  Ca,  USA)  were  used  at  1:50  dilutions  in 
antibody diluents (Dako, Ca, USA). Sections were incubated 
with primary antibody for 1 hour at room temperature. After 
1 hour, all sections were rinsed twice with TBS for 5 minutes 
before incubated with secondary antibody (Dako, Ca, USA) 
for 30 minutes. The sections were rinsed twice with TBS for 
5 minutes. Diaminobenzidine (Dako, Ca, USA) was used as a 
chromogen to verify immunoreactions and hematoxylin was 
used  for  counterstaining.  Negative  control  was  processed 
simultaneously  from  the  same  samples  and  protocol  but 
primary  antibody  step  was  replaced  by  antibody  diluents. 
Colon  adenocarcinoma  sections  were  used  as  a  positive 
control because this tissue was well known to express p27
Kip1. 
p27
Kip1 expression analysis 
p27
Kip1  expression  was  evaluated  by  two  blinded 
pathologists. All nuclear staining, either weak or strong were 
considered  as  a  positive  and  no  staining  detected  was 
considered as a negative. The expressions were scored from 0 
to 4+ depending on the staining intensity. Quantification of 
p27
Kip1  immunohistochemical  expression  score  was  done 
using  five  randomly  ocular  fields  under  200x  microscope 
magnification, where 100 cells were counted in each field. 
The extent and intensity of positive tumour cells were graded 
as 0, none; 1+, weak; 2+, moderate; 3+, strong; and 4+, very 
strong (Yoshimura et al., 2000). All the slides were evaluated 
without  any  knowledge  of  the  patient’s  clinical  data  and 
histopathological reports. 
Statistical analysis 
Data were recorded and statistically analyzed using SPSS 
for Windows Version 17.0 (Chicago, USA) and the statistical 
results  were  considered  significant  for  P  values  less  than 
0.05. Mann-Whitney test was used to compare the expression 
of  p27
Kip1  between  normal,  benign,  and  malignant  prostate 
tissues.  The  Chi-square  test  was  used  to  determine  the 
association  of  clinicopathological  variables  and  p27
Kip1 
expressions. 
Results 
P27
Kip1 was expressed in varying degrees of intensity by 
all the normal, BPH and PCa tissues. In this study, most of 
the  immunoreactivity  was  detected  in  the  nucleus  of  the 
epithelial cells surrounding the acini and occasionally in the 
stromal  cells.  In  normal  prostate  tissues,  the  level  and 
intensity of p27Kip1 staining were uniformly high and the ISSN: 1314-6246  Roduan et al.  J. BioSci. Biotech. 2014, 3(2): 119-125. 
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staining  was  concentrated  within  the  nucle us  but  diffused 
cytoplasmic  staining  was  also  observed.  62  of  63  (98.4%) 
normal prostate tissues strongly expressed p27
Kip1 as shown 
in Figure 1A and Table 1. There was no negative or weak 
staining  observed  in  the  normal  prostate  tissues.  Similar 
staining pattern was seen in BPH, where p27
Kip1 was strongly 
expressed in 77 of 100 (77%) (Figure 1B). In contrast, only 
36  (36%)  and  17  (17%)  of  PCa  cases  showed  strong  and 
moderate p27
Kip1 expressions respectively. The remaining 22 
(22%) of PCa showed weak expressions and 25 (25%) were 
negative.  Low  and  undetectable  p27
Kip1  expressions  were 
observed in the majority of high grade PCa tissues (Figure 1 
D-F).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. p27
Kip1 expressions in the nuclei of the acinar epithelial cells of the normal prostate, BPH, and PCa. A: Normal 
prostate shows very strong p27
Kip1 staining. B: BPH shows strong p27
Kip1 staining. C: PCa Gleason 6 (3+3) shows moderate to 
strong p27
Kip1 staining. D: PCa Gleason 7 (3+4) shows negative to weak p27
Kip1 staining. E: PCa Gleason 8 (4+4) shows 
negative p27
Kip1 staining. F: PCa Gleason 9 (4+5) shows negative p27
Kip1 staining. All samples were counterstained with 
hematoxylin. Original magnification is x200. 
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Table 1. p27
Kip1 expression in the normal prostate, BPH, and PCa 
 
   Distribution of p27
Kip1 staining intensity (%)       
Tissue  0  1+  2+  3+  4+  Total  P 
Normal  0 (0%)  0 (0%)  1 (1.6%)  27 (42.9%)  35 (55.5%)  63   
BPH  3 (3.0%)  4 (4.0%)  16 (16.0%)  60 (60.0%)  17 (17.0%)  100  0.000* 
PCA  25 (25.0%  22 (22.0%)  17 (17.0%)  26 (26.0%)  10 (10.0%)  100  0.000* 
* The difference of p27
Kip1 expressions between  groups was significant at P<0.05. 
 
 
Table 2. Correlation between p27
Kip1 expressions with the clinicopathological parameters 
 
Clinicopathological parameter 
p27
Kip1 score 
Total  P 
0-2 (Low)  3-4 (High) 
Patient’s age in BPH (mean = 68.13ﾱ7.42) 
≤68 
>68 
Patient’s age in PCa (mean = 66.78ﾱ6.23) 
≤66 
>66 
 
10 
13 
 
22 
42 
 
30 
47 
 
18 
18 
 
40 
60 
 
40 
60 
 
0.287 
 
 
0.043* 
 
PSA level in PCa (ng/ml) 
≤4.0 
>4.0 
 
12 
52 
 
17 
19 
 
29 
71 
 
0.003* 
Gleason score (tumour stage) 
≤7 
>7 
 
41 
23 
 
33 
3 
 
74 
26 
 
0.003* 
Tumour amount (%) 
≤5 
>5 
 
18 
46 
 
17 
19 
 
35 
65 
 
0.055 
*The association between p27
Kip1 expressions and clinicopathological parameters was significant at P<0.05. 
 
 
The  association  between  p27
Kip1  expressions  with  the 
clinicopathological  parameters  such  as  patients’  age,  PSA 
level, Gleason score and tumour amount were also studied. 
The intensity of p27
Kip1 and all the parameters were grouped 
into certain cut point. Table 2 summarizes the data relating  
p27
Kip1 expressions to the clinicopathological parameters. 
The cut point for the patient’s age in BPH was set based 
on  the  mean  age  (68.13  ﾱ  7.42).There  was  no  significant 
correlation  between  p27
Kip1  expressions  and  age  group  in 
BPH (P=0.287). In contrast, in PCa (mean age = 66.78ﾱ0.62), 
the  patient’s  age  was  correlated  to  p27
Kip1  expression 
(P=0.043). In addition, there was a significant correlation of 
p27
Kip1  expressions  between  PSA  levels  of  PCa  patients 
(P=0.003)  and  Gleason  scores  (P=0.003).  Tumour  amount 
failed to correlate to p27
Kip1 expressions (P=0.055). 
 
Discussion 
p27
Kip1  down-regulation  has  been  postulated  as  a  key 
event,  which  determination  can  be  a  strong  prognostic 
marker, or can be useful for differential diagnosis in several 
tumour models. In this study, a significant down-regulation 
of p27
Kip1 protein expressions was detected in more than half 
of the malignant cases compared to the benign and normal 
prostate  tissues.  In  accordance  with  other  studies,  a 
significant  loss  or  down-regulation  of  p27
Kip1  expressions 
was widely found in PCa and the protein was significantly 
higher in BPH and normal prostate (Guo et al., 1997; Zheng 
et al., 2004; Nikloveshivili et al., 2008). Our findings clearly 
showed high p27
Kip1 expressions in the normal prostate and 
BPH tissue. Only a small percentage (10%) of the prostate 
tumour tissues expressed high p27
Kip1.  
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The  immunohistochemical  analysis  showed  that  the 
higher  Gleason  score  had  the  greater  total  loss  of  p27
Kip1 
expression  (P=0.003).  Gleason  9  cancer  cells  were  totally 
negative for p27Kip1 staining. This finding was in agreement 
with the previous studies as p27
Kip1 expression was reported 
to be either absent or reduced in high grade prostate cancer 
(Guo et al., 1997; Tsihlias et al., 1998; Cheville et al., 1998; 
Erdamar et al., 1999; Dreher et al., 2004). This indicates that 
p27
Kip1  expression  decreases  when  the  initial  steps  of 
malignant transformation take place and suggested that when 
the neoplasm reaches the invasive stage, down-regulation is 
either maintained or increased. In addition, p38 encoded by 
Jab1  gene  interacts  specifically  with  p27
Kip1  and  over-
expression of p38 can result in translocation of p27
Kip1  from 
the nucleus to the cytoplasm, causing a decreased level of 
p27
Kip1  in the cell by inducing its degradation through the 
ubiquitin/proteasome  pathway  (Pagano  et  al.,  1995). 
Therefore, p38 acts as a  negative regulator to p27
Kip1, and 
their specific binding may explain the regulation of cell cycle 
dependent proteolytic machinery and the selection of key cell 
cycle regulators for degradation (Tomoda et al., 1999). 
Chi-squared  analysis  was  used  to  determine  the 
association  between  p27
Kip1  expression  and  the 
clinicopathological  parameters.  PSA  level  in  PCa  patients 
(P=0.003), Gleason score (P=0.003) and patient’s age in PCa 
(P=0.043)  correlated  with  low  p27
Kip1  expressions.  Low 
expression  of  p27
Kip1  associated  with  elevated  PSA  level, 
increasing Gleason score and increasing age in PCa patients 
were similar with the study conducted by Nikoleishvili et al. 
(2008)  and  Halvorsen  et  al.  (2003).  Tumour  amount 
(P=0.055)  and  patient’s  age  in  BPH  (P=0.287)  does  not 
correlate  with  the  expression  of  the  p27
Kip1  protein. 
Halvorsen et al. (2003) also reported that p27
Kip1 expression 
was  of  borderline  significant  (P=0.054)  associated  with 
tumour amount as similar to this study. This result may be 
due to different methodologies, sample size, and cut points 
used to define p27
Kip1 expression in this study as compared to 
other studies (Drobnjak et al., 2003).  
p27
Kip1  is  rarely  mutated  in  human  tumours  including 
localized  prostate  carcinoma,  however  the  homozygous 
deletion involving p27
Kip1 locus or loss of p27
Kip1 expression 
raised the possibility that genetic alteration of this gene may 
play  an  important  role  in  prostate  carcinoma  (Kibel  et  al., 
2003).  Guo  et  al.  (1997)  found  that  reduced  p27
Kip1 
expression correlated to high proliferative index and tumour 
grade.  They  also  found  that  4  of  5  metastatic  samples 
demonstrated decreased staining intensity. Cordon-Cardo et 
al. (1998) demonstrated low expression of p27
Kip1 in 83% of 
metastatic  samples.  Other  studies  found  that  decreased 
p27
Kip1  expression  does  not  only  correlate  with  decreased 
disease-free survival, but also overall survival (Cote et al., 
1998). In addition, Cheville et al. (1998) found that decreased 
p27
Kip1  expression  correlated  with  adverse  pathological 
features. Besides that, animal based studies demonstrated that 
loss  of  p27
Kip1  correlated  with  loss  of  Nkx3-1  in  mouse 
prostate carcinogenesis (Gary et al., 2004). Although genetic 
alteration of CDK inhibitor in prostate carcinoma are rare, 
but it still occur in certain cases because translational control 
is primarily responsible for the regulation of p27
Kip1 during 
cell cycle progression in response to TGF-β (Hengst & Reed, 
1996). Tomoda et al. (1999) reported substitution of glycine 
for  valine  in  p27
Kip1  polymorphism,  causing  p38
jab1  to 
promote  the  phosphorylation  and  cytoplasmic  translocation 
of p27
Kip1 for its subsequent degradation in  the cytoplasm, 
therefore lower the level of p27
Kip1 in the nucleus. Kibel & 
Isaacs  (2000)  also  conclude  that  p27
Kip1  is  the  strongest 
candidate  as  a  biomarker.  They  further  mentioned  that 
increased  p27
Kip1  expression  appears  to  correlate  with 
improved pathological features and disease-free survival. 
In  addition,  several  functions  have  been  described  to  a 
p27
Kip  protein,  but  loss  of  its  expression  is  thought  to  be 
tumourigenic and may lead to tumour progression. Other than 
those  functions,  p27
Kip  is  also  involved  in  apoptosis 
promotion,  regulation  of  drugs  resistance  in  solid  tumours 
and  have  protective  role  in  inflammatory  injury  (Ponce-
Castaneda  et  al.,  1995).  The  fact  that  loss  of  p27
Kip1 
expressions in mice significantly affects tumour progression, 
in conjunction with the observation that its protein level is 
reduced in human tumour suggests that restoring p27
Kip1 may 
be beneficial in prostate cancer therapy (Blain et al., 2003). 
Conclusion 
In  conclusion,  we  suggest  that  p27
Kip1  might  have  a 
significant  role  in  prostate  cancer  development  and 
progression. There are powerful arguments and suggestions 
that p27
Kip1should be evaluated further as one of the potential 
therapeutic targets for prostate cancer or other types of cancer 
in Malaysia. Additional studies are required to examine the 
potential use of p27
Kip1 as a prognostic marker to strengthen 
the  evidences  for  better  aggressive  screening,  prophylaxis, 
and treatment of prostate cancer.  
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